AGF US Market Neutral Anti-Beta Fund
BTAL
4 hedge funds and large institutions have $336K invested in AGF US Market Neutral Anti-Beta Fund in 2014 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1.1% less ownership
Funds ownership: 12.79% → 11.68% (-1.1%)
8% less capital invested
Capital invested by funds: $366K → $336K (-$30K)
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
-$21.5K |
| 2 |
Citigroup
New York
|
-$17.2K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4K |
BTAL Hedge Fund Activity: Q1 2014 in Review
4 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in AGF US Market Neutral Anti-Beta Fund (BTAL) for Q1 2014, worth a combined $336K — down 8.2% from $366K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BTAL and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Virtu KCG Holdings, adding an estimated $11.9K. The largest seller was UBS, cutting an estimated $21.5K.
- 4 institutional investors held AGF US Market Neutral Anti-Beta Fund (BTAL) as of Q1 2014, down from 5 in Q4 2013.
- Funds reported $336K of AGF US Market Neutral Anti-Beta Fund stock for Q1 2014, down 8.2% quarter-over-quarter.
- 0 funds opened new AGF US Market Neutral Anti-Beta Fund positions in Q1 2014 and 1 closed out, a net change of -1 holder.
- The largest AGF US Market Neutral Anti-Beta Fund buyer in Q1 2014 was Virtu KCG Holdings, an estimated $11.9K added.
- The largest AGF US Market Neutral Anti-Beta Fund seller in Q1 2014 was UBS, an estimated $21.5K sold.
Based on aggregated 13F filings for Q1 2014.